Abstract
Background
Collagenase clostridium histolyticum (CCH) has proven to be both safe and effective in the treatment of Dupuytren disease (DD). The medium-term outcomes are similar to those achieved with surgery, and most adverse effects are self-limiting and considered to be mild or moderate.
Objective
Our objective was to conduct a systematic review of the adverse effects of CCH in DD since the release of the drug to evaluate the incidence, severity, classification, and definitions of these effects.
Methods
We analyzed the literature in terms of modifications to the original treatment protocol and grouped adverse effects according to their pathophysiological origin.
Results
We included 28 clinical studies and five case reports or case series analyzing 4456 patients with a mean age of 63.6 years. Mean follow-up was 7.07 months (range 3–24); the mean number of patients per study was 148 (range 5–1082). The studies did not classify the adverse effects they reported into groups. The most common effects were peripheral edema (54.4%), bruising (42.9%), and upper limb pain (28.3%). Significant biases were observed for use of terminology, demarcation of sites of involvement, severity criteria, and assessment methods.
Conclusion
A simpler and clearer consensus-based classification system would enable better evaluation and comparison of the adverse effects of CCH in the treatment of DD. Consideration of inflammatory phenomena as part of the drug’s mechanism of action would significantly reduce overall rates of adverse effects.
Similar content being viewed by others
References
Peimer CA, Blazar P, Coleman S, Kaplan FTD, Smith T, Lindau T. Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium Histolyticum (CORDLESS Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study): 5-year data. J Hand Surg Am. 2015;40:1597–605.
Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FTD, Meals RA, et al. Injectable collagenase clostridium histolyticum for dupuytren’s contracture. N Engl J Med. 2009;361:968–79.
Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP. Safety and tolerability of collagenase clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur. 2015;40(2):141–9.
Warwick DJ, Graham D, Worsley P. New insights into the immediate outcome of collagenase injections for Dupuytren’s contracture. J Hand Surg Eur. 2016;41(6):583–8. doi:10.1177/1753193415600670.
Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology, 8th ed. Philadelphia: Elsevier; 2014.
Radice M, Brun P, Bernardi D, Fontana C, Cortivo R, Abatangelo G. Clostridial collagenase releases bioactive fragments from extracellular matrix molecules. J Burn Care Rehabil. 1999;20:282–91.
Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg. 2010;35(2027–2038):e1.
Peimer CA, McGoldrick CA, Fiore GJ. Nonsurgical treatment of Dupuytren’s contracture: 1-year US post-marketing safety data for collagenase clostridium histolyticum. Hand (N Y). 2012;7:143–6.
Bendon CL, Giele HP. Collagenase for Dupuytren’s disease of the thumb. J Bone Jt Surg Br. 2012;94:1390–2.
Coleman S, Gilpin D, Tursi J, Kaufman G, Jones N, Cohen B. Multiple concurrent collagenase clostridium histolyticum injections to dupuytren’s cords: an exploratory study. BMC Musculoskelet Disord. 2012;13:61.
McMahon HA, Bachoura A, Jacoby SM, Zelouf DS, Culp RW, Osterman AL. Examining the efficacy and maintenance of contracture correction after collagenase clostridium histolyticum treatment for Dupuytren’s disease. Hand (N Y). 2013;8:261–6.
Alberton F, Corain M, Garofano A, Pangallo L, Valore A, Zanella V, et al. Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: report of 40 cases. Musculoskelet Surg. 2014;98:225–32.
Martín-Ferrero MA, Simon-Perez C, Rodriguez-Mateos JI, Garcia-Medrano B, Hernandez-Ramajo R, Brotat-Garcia M. Tratamiento de la enfermedad de Dupuytren mediante la colagenasa del Clostridium histolyticum. Rev Esp Cir Ortop Traumatol. 2013;57:398–402.
Nydick JA, Olliff BW, Garcia MJ, Hess AV, Stone JD. A comparison of percutaneous needle fasciotomy and collagenase injection for dupuytren disease. J Hand Surg. 2013;38:2377–80.
Witthaut J, Jones G, Skrepnik N, Kushner H, Houston A, Lindau TR. Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg. 2013;38:2–11.
Leclère F-M, Mathys L, Vögelin E. Traitement de la maladie de Dupuytren par collagénase injectable, évaluation de l’échographie assistée. Chir Main. 2014;33:196–203.
Manning CJ, Delaney R, Hayton MJ. Efficacy and tolerability of Day 2 manipulation and local anaesthesia after collagenase injection in patients with Dupuytren’s contracture. J Hand Surg Eur. 2014;39:466–71.
Sood A, Therattil PJ, Paik AM, Simpson MF, Lee ES. Treatment of Dupuytren disease with injectable collagenase in a veteran population: a case series at the department of veterans affairs new jersey health care system. Eplasty. 2014;14:e13.
Coleman S, Gilpin D, Kaplan FTD, Houston A, Kaufman GJ, Cohen BM, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg. 2014;39:57–64.
Warwick D, Arner M, Pajardi G, Reichert B, Szabo Z, Masmejean EH, et al. Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur. 2015;40(2):124–32.
Verheyden JR. Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique. J Hand Surg Eur. 2015;40(2):133–40.
Considine S, Heaney R, Hirpara KM. Early results of the use of collagenase in the treatment of Dupuytren’s contracture. Ir J Med Sci. 2015;184:323–7.
Zhou C, Hovius SER, Slijper HP, Feitz R, Van Nieuwenhoven CA, Pieters AJ, et al. Collagenase clostridium histolyticum versus limited fasciectomy for Dupuytren’s contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg. 2015;136:87–97.
Kaplan FTD, Badalamente MA, Hurst LC, Merrell GA, Pahk R. Delayed manipulation after collagenase clostridium histolyticum injection for Dupuytren contracture. Hand (N Y). 2015;10(3):578–82.
Gaston RG, Larsen SE, Pess GM, Coleman S, Dean B, Cohen BM, et al. The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, Multicenter Study. J Hand Surg. 2015;40:1963–71.
Atroshi I, Nordenskjöld J, Lauritzson A, Ahlgren E, Waldau J, Waldén M. Collagenase treatment of Dupuytren’s contracture using a modified injection method. Acta Orthop. 2015;86:310–5.
Tay TKW, Tien H, Lim EYL. Comparison between collagenase injection and partial fasciectomy in the treatment of Dupuytren’s contracture. Hand Surg. 2015;20:386–90.
Waters MJ, Belsky MR, Blazar PE, Leibman MI, Ruchelsman DE. Collagenase enzymatic fasciotomy for dupuytren contracture in patients on chronic immunosuppression. Am J Orthop. 2015;44:518–21.
Haerle M, Witthaut J, Giunta R, Huscher D, Pieper L, Kirch W, et al. Treatment of Dupuytren´s contracture with collagenase clostridium histolyticum under clinical practice conditions: ReDUCTo study. GMS Ger Plast Reconstr Aesthet Surg. 2015;5:Doc 06. doi:10.3205/gpras000034
Arora R, Kaiser P, Kastenberger T-J, Schmiedle G, Erhart S, Gabl M. Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren’s disease. Oper Orthop Traumatol. 2016;28:30–7.
Hirata H, Tanaka K, Sakai A, Kakinoki R, Ikegami H, Tateishi N. Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren’s contracture in non-Caucasian Japanese patients (CORD-J Study): the first clinical trial in a non-Caucasian population. J Hand Surg Eur. 2017 (Epub 16 June 2016).
Wize J, Wojtecka-Łukasik E, Maśliński S. Collagen-derived peptides release mast cell histamine. Agents Actions. 1986;18:262–5.
Patterson RW, Li Z, Smith BP, Smith TL, Koman LA. Complex regional pain syndrome of the upper extremity. J Hand Surg Am. 2011;36:1553–62.
Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med. 2007;8:326–31.
King ICC, Belcher HJCR. Cold intolerance following collagenase clostridium histolyticum treatment for Dupuytren contracture. J Hand Surg. 2014;39:808–9.
Rozen WM, Edirisinghe Y, Crock J. Late complications of clinical clostridium histolyticum collagenase use in Dupuytren’s disease. PLoS One. 2012;7:e43406.
Scherman P, Jenmalm P, Dahlin LB. Early outcome of needle fasciotomy and collagenase injection in treatment of dupuytren contracture: a 2-center prospective randomized clinical trial. J Hand Surg. 2014;39:e31.
Sanjuan-Cervero R, Franco N. Vasospasm after collagenase clostridium histolyticum infiltration in Dupuytren’s contracture. Int J Med Pharm Case Rep. 2014;1:42–8.
Swanson JW, Watt AJ, Vedder NB. Skin graft loss resulting from collagenase clostridium histolyticum treatment of Dupuytren contracture: case report and review of the literature. J Hand Surg. 2013;38:548–51.
Eberlin KR, Kobraei EM, Nyame TT, Bloom JM, Upton J. Salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum. Plastic Reconstr Surg. 2015;135:1000e–6e.
Bond MD, Van Wart HE. Purification and separation of individual collagenases of clostridium histolyticum using red dye ligand chromatography. Biochem. 1984;23:3077–85.
Bond MD, Van Wart HE. Characterization of the individual collagenases from clostridium histolyticum. Biochem. 1984;23:3085–91.
Bond MD, Van Wart HE. Relationship between the individual collagenases of clostridium histolyticum: evidence for evolution by gene duplication. Biochem. 1984;23:3092–9.
McGrouther DA. Dupuytren´s contracture. In: Green DP, Pederson WC, Hotchkiss RN, Wolfe SW, editors. Green’s operative hand surgery. 5th ed. Madrid: Marban Editorial; 2007. p. 159–86.
Postlethwaite AE, Kang AH. Collagen-and collagen peptide-induced chemotaxis of human blood monocytes. J Exp Med. 1976;143:1299–307.
Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci USA. 1978;75:871–5.
Velnar T, Bailey T, Smrkolj V. The wound healing process: an overview of the cellular and molecular mechanisms. J Int Med Res. 2009;37:1528–42.
Grinnell F, Zhu M, Parks WC. Collagenase-1 complexes with alpha2-macroglobulin in the acute and chronic wound environments. J Invest Dermatol. 1998;110:771–6.
Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG. The collagen substrate specificity of human neutrophil collagenase. J Biolo Chem. 1987;262:10048–52.
Hovius SER, Kan HJ, Smit X, Selles RW, Cardoso E, Khouri RK. Extensive percutaneous aponeurotomy and lipografting: a new treatment for Dupuytren disease. Plast Reconstr Surg. 2011;128:221–8.
Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg. 2007;32:767–74.
Sanjuan-Cervero R, Vaquero M, Carrera-Hueso FJ. Re: salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum. Plast Reconstr Surg. 2016;137:760e–1e.
Hay DC, Louie DL, Earp BE, Kaplan FTD, Akelman E, Blazar PE. Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase (Xiaflex). J Hand Surg Eur. 2014;39:463–5.
Acknowledgements
This article is part of the Doctoral Thesis of Rafael Sanjuan-Cervero within the Doctoral Program in Pharmacy at Granada University, Spain.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This research received no specific grants from any funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest
Rafael Sanjuan-Cerveró, Francisco J Carrera-Hueso, Pedro Vazquez-Ferreiro, and Diego Gomez-Herrero have no conflicts of interest relevant to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Sanjuan-Cerveró, R., Carrera-Hueso, F.J., Vazquez-Ferreiro, P. et al. Adverse Effects of Collagenase in the Treatment of Dupuytren Disease: A Systematic Review. BioDrugs 31, 105–115 (2017). https://doi.org/10.1007/s40259-017-0211-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-017-0211-z